ID   UPPL1541
AC   CVCL_C0CT
DR   ABM; T8245
DR   Wikidata; Q112930527
RX   PubMed=29784854;
CC   Characteristics: Displays a similar expression profiles to luminal-like molecular subtype bladder cancers in humans (ABM=T8245).
CC   Doubling time: 24-36 hours (ABM=T8245).
CC   Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten.
CC   Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53.
CC   Genetic integration: Method=Transgenic mouse; Gene=MGI; MGI:1352467; Esr1 (Note=Ligand binding domain; with p.Gly525Arg. Fused to Cre = CreERT2).
CC   Genetic integration: Method=Transgenic mouse; Gene=UniProtKB; P06956; Escherichia phage P1 cre (Note=Fused to ligand domain of mouse Esr1 = CreERT2).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Cell type: Urothelial cell; CL=CL_0000731.
CC   Breed/subspecies: C57BL/6 Upk3a-CreERT2, Trp53L/L, PtenL/L, Rosa26LSL-Luc transgenic.
DI   NCIt; C25823; Mouse bladder transitional cell carcinoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 7
//
RX   PubMed=29784854; DOI=10.1158/0008-5472.CAN-18-0173; PMCID=PMC6157276;
RA   Saito R., Smith C.C., Utsumi T., Bixby L.M., Kardos J., Wobker S.E.,
RA   Stewart K.G., Chai S.-J., Manocha U., Byrd K.M., Damrauer J.S.,
RA   Williams S.E., Vincent B.G., Kim W.Y.;
RT   "Molecular subtype-specific immunocompetent models of high-grade
RT   urothelial carcinoma reveal differential neoantigen expression and
RT   response to immunotherapy.";
RL   Cancer Res. 78:3954-3968(2018).
//